Disease or Syndrome – Page 15

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

2 months ago talkbio0Tagged Autoimmune Diseases, Collaboration, Drug Discovery, Immunology, molecular glue degraders, Monte Rosa Therapeutics, Novartis, QuEEN, royalties, upfront payment

Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration

RFK Jr. Names 8 New ACIP Members, Replacing Prior Committee Before Key Vaccine Votes

2 months ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), COVID19 (disease), measles, RFK Jr., Robert F. Kennedy Jr., Shakeup, vaccine advisors, Vaccine Safety

RFK Jr.; ACIP; CDC; vaccine advisors; COVID-19; measles; Robert F. Kennedy Jr.; vaccine safety; committee shakeup

Lila Sciences Raises $235M to Expand AI Science Factories

2 months ago talkbio0Tagged Artificial Intelligence, Autonomous Research, Biotechnology, Funding, Lila Sciences, Series

Lila Sciences; AI Science Factories; Autonomous Research; Biotechnology; Series A Funding

aTyr’s Steroid-Sparing Lung Disease Drug Disappoints in Late-Stage Trial

2 months ago talkbio0Tagged aTyr, efzofitimod, Lung Diseases, Interstitial, Pharma, Sarcoidosis, Pulmonary, steroid-sparing

aTyr Pharma; efzofitimod; steroid-sparing; pulmonary sarcoidosis; interstitial lung disease

Eli Lilly Pauses UK Biotech Incubator Plans Amid Concerns Over NHS Drug Pricing

2 months ago talkbio0Tagged Biological Science Disciplines, biotech incubator, biotech industry, Eli, Eli Lilly, Gateway Labs, Government, Investments, Nance-Horan syndrome, Pauses, pharmaceutical innovation, UK

Eli Lilly; Gateway Labs; UK biotech incubator; pause; investment; NHS drug spending; life sciences; biotech industry; government funding; pharmaceutical innovation

Capsida Suspends Gene Therapy Trial After First Patient Death

2 months ago talkbio0Tagged CAP-002, Capsida Biotherapeutics, Clinical Trial Suspension, Encephalopathies, gene therapy, Patient Death, STXBP1 gene, United States Food and Drug Administration

Capsida Biotherapeutics; gene therapy; CAP-002; clinical trial suspension; STXBP1 encephalopathy; patient death; FDA

FibroGen Settles with SEC for $1.25M Over Roxadustat Data Tampering Allegations

2 months ago talkbio0Tagged Anemia, cardiovascular safety, Clinical Trials, data manipulation, FibroGen, Kin-Hung Peony Yu, Phase 3, roxadustat, seconds, settlement, United States Food and Drug Administration

FibroGen; SEC; roxadustat; data manipulation; settlement; Kin-Hung Peony Yu; phase 3 clinical trial; anemia drug; cardiovascular safety; FDA

Intercept Withdraws Ocaliva from US Market After FDA Safety Concerns

2 months ago talkbio0Tagged Clinical Trials, concerns, Drug withdrawal syndrome, Injury of liver, Intercept Pharmaceuticals, Liver diseases, Ocaliva, Primary Biliary Cholangitis, regulatory setbacks, Safety, United States Food and Drug Administration

Intercept Pharmaceuticals; Ocaliva; liver disease; primary biliary cholangitis; FDA; drug withdrawal; safety concerns; liver injury; clinical trial hold; regulatory setbacks

Merck Moves All R&D Operations Out of UK, Citing Unfavorable Environment

2 months ago talkbio0Tagged Biological Science Disciplines, Brexit impact, Drug Discovery, Government, Investments, layoffs, London Bioscience Innovation Centre, Merck, Multiple Sulfatase Deficiency Disease, Relocation of home or business, UK

Merck; MSD; R&D relocation; UK life sciences; drug discovery; Brexit impact; London Bioscience Innovation Centre; Francis Crick Institute; government investment; layoffs

Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA

2 months ago talkbio0Tagged Approved, Avidity, Biosciences, Blackfoot language, Breakthrough Therapy, Clinical Trials, Functional, Improvements, Muscular Dystrophy, Duchenne, skipping, Submission, United States Food and Drug Administration

Avidity Biosciences; del-zota; DMD; Duchenne muscular dystrophy; FDA approval; functional improvements; exon 44 skipping; Breakthrough Therapy; clinical trial; BLA submission